Literature DB >> 25276378

The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers.

Qingli Jiao1, Aiguo Wu1, Guoli Shao1, Haoyu Peng1, Mengchuan Wang1, Shufeng Ji1, Peng Liu1, Jian Zhang1.   

Abstract

Triple negative breast cancer (TNBC) is one type of breast cancer (BC), which is defined as negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (Her2). Its origins and development seem to be elusive. And for now, drugs like tamoxifen or trastuzumab which specifically apply to ER, PR or Her2 positive BC seem unforeseeable in TNBC clinical treatment. Due to its extreme malignancy, high recurrence rate and poor prognosis, a lot of work on the research of TNBC is needed. This review aims to summarize the latest findings in TNBC in risk factors, possible therapeutic targets and possible prognostic makers.

Entities:  

Keywords:  Triple negative breast cancer (TNBC); prognostic marker; risk factor; therapeutic target

Year:  2014        PMID： 25276378      PMCID： PMC4178098          DOI： 10.3978/j.issn.2072-1439.2014.08.13

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


  66 in total

1.  High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells.

Authors:  Jewel Daniel; Jonathan Coulter; Ju-Hyung Woo; Kathleen Wilsbach; Edward Gabrielson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-14       Impact factor: 11.205

2.  Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.

Authors:  Anna-Karin Falck; Pär-Ola Bendahl; Gunilla Chebil; Hans Olsson; Mårten Fernö; Lisa Rydén
Journal:  Breast Cancer Res Treat       Date:  2013-06-27       Impact factor: 4.872

3.  MUC1 regulates nuclear localization and function of the epidermal growth factor receptor.

Authors:  Benjamin G Bitler; Aarthi Goverdhan; Joyce A Schroeder
Journal:  J Cell Sci       Date:  2010-04-20       Impact factor: 5.285

Review 4.  A review of triple-negative breast cancer.

Authors:  Roohi Ismail-Khan; Marilyn M Bui
Journal:  Cancer Control       Date:  2010-07       Impact factor: 3.302

Review 5.  Triple-negative breast cancer: risk factors to potential targets.

Authors:  Bryan P Schneider; Eric P Winer; William D Foulkes; Judy Garber; Charles M Perou; Andrea Richardson; George W Sledge; Lisa A Carey
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

6.  Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.

Authors:  Ramesh K Ramanathan; Kenneth M Lee; John McKolanis; Elizabeth Hitbold; Wolfgang Schraut; Arthur J Moser; Elizabeth Warnick; Theresa Whiteside; Jennifer Osborne; Hyoung Kim; Roger Day; Monica Troetschel; Olivera J Finn
Journal:  Cancer Immunol Immunother       Date:  2004-09-14       Impact factor: 6.968

Review 7.  Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.

Authors:  Ana Bosch; Pilar Eroles; Rosa Zaragoza; Juan R Viña; Ana Lluch
Journal:  Cancer Treat Rev       Date:  2010-01-08       Impact factor: 12.111

8.  Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer.

Authors:  Jennifer B Dennison; Jennifer R Molina; Shreya Mitra; Ana M González-Angulo; Justin M Balko; María G Kuba; Melinda E Sanders; Joseph A Pinto; Henry L Gómez; Carlos L Arteaga; Robert E Brown; Gordon B Mills
Journal:  Clin Cancer Res       Date:  2013-05-22       Impact factor: 12.531

9.  LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients.

Authors:  Sung Gwe Ahn; Seung Myung Dong; Akira Oshima; Woo Ho Kim; Hak Min Lee; Seung Ah Lee; Seung-Hyun Kwon; Ji-Hae Lee; Jae Myun Lee; Joon Jeong; Hy-De Lee; Jeffrey E Green
Journal:  Breast Cancer Res Treat       Date:  2013-08-10       Impact factor: 4.872

10.  Mutant p53-Notch1 Signaling Axis Is Involved in Curcumin-Induced Apoptosis of Breast Cancer Cells.

Authors:  Yun-Hee Bae; Jong Hyo Ryu; Hyun-Joo Park; Kwang Rok Kim; Hee-Jun Wee; Ok-Hee Lee; Hye-Ock Jang; Moon-Kyoung Bae; Kyu-Won Kim; Soo-Kyung Bae
Journal:  Korean J Physiol Pharmacol       Date:  2013-07-30       Impact factor: 2.016
View more
  15 in total

1.  Fragment-based in silico modeling of multi-target inhibitors against breast cancer-related proteins.

Authors:  Alejandro Speck-Planche; M Natália D S Cordeiro
Journal:  Mol Divers       Date:  2017-02-13       Impact factor: 2.943

2.  Microarray expression profiling of dysregulated long non-coding RNAs in triple-negative breast cancer.

Authors:  Chen Chen; Zhilu Li; Yuan Yang; Tingxiu Xiang; Weihong Song; Shengchun Liu
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

3.  Multiple effects of Xihuang pill aqueous extract on the Hs578T triple-negative breast cancer cell line.

Authors:  Wenxian Zheng; Shuyan Han; Shantong Jiang; Lina Pang; Xiaohong Li; Xijuan Liu; Minhua Cao; Pingping Li
Journal:  Biomed Rep       Date:  2016-09-30

Review 4.  Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer.

Authors:  Gordon Greville; Amanda McCann; Pauline M Rudd; Radka Saldova
Journal:  Epigenetics       Date:  2016-09-30       Impact factor: 4.528

5.  Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.

Authors:  Seema Thakur; Rajesh K Grover; Sanjay Gupta; Ajay K Yadav; Bhudev C Das
Journal:  PLoS One       Date:  2016-07-12       Impact factor: 3.240

6.  St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up.

Authors:  A K Falck; A Röme; M Fernö; H Olsson; G Chebil; P O Bendahl; L Rydén
Journal:  Br J Surg       Date:  2016-02-09       Impact factor: 6.939

7.  The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy.

Authors:  Zhi-Rui Zhou; Zhao-Zhi Yang; Shao-Jia Wang; Li Zhang; Ju-Rui Luo; Yan Feng; Xiao-Li Yu; Xing-Xing Chen; Xiao-Mao Guo
Journal:  Acta Pharmacol Sin       Date:  2017-01-02       Impact factor: 6.150

8.  Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.

Authors:  Leonardo Mirandola; Elisa Pedretti; Jose A Figueroa; Raffaella Chiaramonte; Michela Colombo; Caroline Chapman; Fabio Grizzi; Federica Patrinicola; W Martin Kast; Diane D Nguyen; Rakhshanda Layeequr Rahman; Naval Daver; Peter Ruvolo; Sean M Post; Robert S Bresalier; Maurizio Chiriva-Internati
Journal:  Oncotarget       Date:  2017-08-10

9.  Selection of Novel Peptides Homing the 4T1 CELL Line: Exploring Alternative Targets for Triple Negative Breast Cancer.

Authors:  Vera L Silva; Debora Ferreira; Franklin L Nobrega; Ivone M Martins; Leon D Kluskens; Ligia R Rodrigues
Journal:  PLoS One       Date:  2016-08-22       Impact factor: 3.240

10.  Methionine deprivation suppresses triple-negative breast cancer metastasis in vitro and in vivo.

Authors:  Hyein Jeon; Jae Hwan Kim; Eunjung Lee; Young Jin Jang; Joe Eun Son; Jung Yeon Kwon; Tae-Gyu Lim; Sunghoon Kim; Jung Han Yoon Park; Jong-Eun Kim; Ki Won Lee
Journal:  Oncotarget       Date:  2016-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.